title: Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
authors.affiliation: Department of Hematology and Oncology, Marienhospital Herne, University of Bochum, Herne, Germany. beate.schultheis@marienhospital-herne.de
authors.forename: Beate
authors.initials: B
authors.lastname: Schultheis
authors.forename: Henrike
authors.initials: H
authors.lastname: Neumann
authors.forename: Renée
authors.initials: R
authors.lastname: Roy
authors.forename: Vera
authors.initials: V
authors.lastname: Heuer
authors.forename: Gerhard
authors.initials: G
authors.lastname: Kummer
authors.forename: Dirk
authors.initials: D
authors.lastname: Strumberg
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage; D000068258:Bevacizumab; D006801:Humans; D020714:Maximum Tolerated Dose; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives; D017239:Paclitaxel / Q000008:administration & dosage; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D017239:Paclitaxel